alpha-chymotrypsin and Oropharyngeal-Neoplasms

alpha-chymotrypsin has been researched along with Oropharyngeal-Neoplasms* in 2 studies

Trials

1 trial(s) available for alpha-chymotrypsin and Oropharyngeal-Neoplasms

ArticleYear
Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2007, Volume: 183, Issue:3

    To investigate the efficacy and safety of Wobe-Mugos E (proteolytic enzymes) for amelioration of early side effects of radiotherapy for head-and-neck tumors, particularly oral mucositis.. The study was a prospective, randomized, multicenter, placebo-controlled, triple-blind phase III study with parallel groups. 69 patients with carcinomas of the oropharynx or the oral cavity were enrolled between 1996 and 2000 in five centers; 54 of these were recruited in Dresden. Of the 69 patients, 61 (Dresden: 46) were available for analysis. The proteolytic enzymes tested (Wobe-Mugos E) comprised papain 100 mg, trypsin 40 mg, and chymotrypsin 40 mg.. Wobe-Mugos E was well tolerated. For the maximum mucositis scores, no statistically significant differences were found between the placebo and the verum group. The average mucositis score over weeks 1-6 revealed a significant difference in favor of the placebo arm, based on an earlier onset of mucositis in the Wobe-Mugos E group.. The present study failed to demonstrate any effect of treatment with Wobe-Mugos E on radiotherapy side effects in patients treated for head-and-neck tumors. In particular, there was no beneficial effect on radiation-induced early oral mucositis.

    Topics: Adult; Aged; Chymotrypsin; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neoplasm Staging; Oropharyngeal Neoplasms; Papain; Prospective Studies; Radiation Injuries; Radiotherapy, Adjuvant; Stomatitis; Treatment Failure; Trypsin

2007

Other Studies

1 other study(ies) available for alpha-chymotrypsin and Oropharyngeal-Neoplasms

ArticleYear
Prognostic Role of
    Anticancer research, 2022, Volume: 42, Issue:11

    The oral bacteria involved in the development of periodontitis alter the tissue conditions and modify immune responses in a way that may also influence tumor development. We investigated the prevalence of R gingipain (Rgp), a key virulence factor of the oral pathobiont Porphyromonas gingivalis, and the tissue-destructive enzymes matrix metalloproteinase 8 (MMP-8) and 9 (MMP-9) in 202 unselected consecutive oropharyngeal squamous cell carcinoma (OPSCC) samples. We further investigated the relationships between these factors and human papillomavirus (HPV) status, Treponema denticola chymotrypsin-like proteinase (Td-CTLP) immunoexpression, clinical parameters, and patient outcome.. Clinicopathological data were derived from university hospital records. Rgp, MMP-8, and MMP-9 immunoexpression was evaluated by immunohistochemistry; the immunohistochemistry of Td-CTLP and HPV has been described earlier for this patient series. Cox regression analysis including death by causes other than OPSCC as a competing risk served to assess sub distribution hazard ratios.. In multivariable survival analysis, positive tumoral MMP-9 immunoexpression predicted poor prognosis among all patients [sub distribution hazard ratio (SHR)=2.4; confidence interval (CI)=1.2-4.4, p=0.008], and especially among those with HPV-negative OPSCC (SHR=3.5; CI=1.7-7.3, p=0.001). Positive immunoexpression of Rgp in inflammatory cells was associated with favorable outcome among all patients (SHR=0.5, CI=0.2-0.9, p=0.021) and among those with HPV-negative disease (SHR=0.4, CI=0.2-0.9, p=0.022).. Our results suggest that tumoral MMP-9 may be related to poor outcome in OPSCC, especially in HPV-negative disease, while Rgp immunoexpression in inflammatory cells is associated here with better disease-specific survival (DSS).

    Topics: Chymotrypsin; Gingipain Cysteine Endopeptidases; Head and Neck Neoplasms; Humans; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Oropharyngeal Neoplasms; Papillomaviridae; Papillomavirus Infections; Porphyromonas gingivalis; Prognosis; Squamous Cell Carcinoma of Head and Neck; Virulence Factors

2022